.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Metastatic Triple Negative Breast Cancer: IMpassion130

EP. 1: IMpassion130: Design and Preliminary Efficacy

May 8th 2020

EP. 2: PD-L1 Assay PFS and OS Concordance

May 8th 2020

EP. 3: PD-L1 Immune-Related Adverse Events

May 8th 2020

EP. 4: ICI Combination Therapy Versus Monotherapy

May 8th 2020

EP. 5: Adjuvant I/O in TNBC

May 8th 2020

EP. 6: TNBC: Updated Efficacy Results From IMpassion130

May 8th 2020

EP. 7: Analysis of IMpassion130: PD-L1 Testing in Advanced TNBC

May 8th 2020

EP. 8: IMpassion130: Addressing Immune-Related AEs in TNBC Management

May 8th 2020

EP. 9: TNBC: Using Checkpoint Inhibitors Alone or With Chemotherapy

May 8th 2020

EP. 10: Optimizing Perioperative Treatment Strategies in TNBC

May 8th 2020